Tuesday, September 30, 2014 | 8:30 AM - 5:00 PM
Keynote Speaker: Nobel Laureate Robert J. Lefkowitz (Duke University Medical Center)
Speakers: Bryan Roth (University of North Carolina at Chapel Hill School of Medicine), Terry Kenakin (University of North Carolina at Chapel Hill School of Medicine), Marc G. Caron (Duke University Medical Center), Laura Bohn (The Scripps Research Institute), Michael Ehlers (Pfizer), JoAnn Trejo (University of California-San Diego), Jonathan Violin (Trevena, Inc.)
Hear academic, industry, basic and translational researchers, including Nobel Laureate Robert Lefkowitz (Duke University Medical Center) and discuss the development of functionally selective GPCR-biased ligands for CV and CNS disease drug discovery.
Tuesday, October 28, 2014 | 8:30 AM - 5:00 PM
Speaker: Michael S. Conte (University of California-San Francisco, San Francisco, CA), Milan Fiala (David Geffen School of Medicine at UCLA, Los Angeles, CA), Gabrielle Fredman (Columbia University, New York, NY), Bruce Levy (Harvard University, Brigham and Women's Hospital, Boston, MA), Dipak Panigrahy (Beth Israel Deaconess Medical Center, Boston, MA), Mauro Perretti (William Harvey Research Institute, London, UK), Charles N. Serhan (Harvard University, New York, NY), Patricia J. Sime (University of Rochester School of Medicine, Rochester, NY), Rudy Tanzi (Massachusetts General Hospital, Charlestown, MA)
Uncontrolled, chronic inflammation plays a key role in the progression of many diseases, and elucidation of biochemical pathways provides novel targets. This symposium reviews discoveries, approaches and opportunities for treatment and prevention.
Monday, November 3, 2014 | 8:00 AM - 4:30 PM
Speakers: Erik W.G.M. Boddeke (University Medical Center Groningen, The Netherlands), Oleg Butovsky (Brigham and Women's Hospital and Harvard Medical School, Boston, MA), Philip L. De Jager (Harvard University and Brigham and Women's Hospital, Boston, MA), Joseph El Khoury (Massachusetts General Hospital and Harvard Medical School, Boston, MA), Miriam Merad (Icahn School of Medicine at Mt. Sinai, New York, NY), Michael C. Oldham (University of California, San Francisco, San Francisco, CA), Bin Zhang (Icahn School of Medicine at Mt. Sinai, New York, NY)
Next generation sequencing of Alzheimer’s disease (AD) progression reveals gene networks within microglial pathways. This symposium focuses on microglia biology, molecular signatures specific to microglial phenotypes, and phenotype modulation.
Tuesday, December 9, 2014 | 8:00 AM - 5:00 PM
Speakers: Matthew D. Breyer (Eli Lilly, Indianapolis, IN), Frank C. Brosius (University of Michigan Medical School, Ann Arbor, MI), Benjamin D. Humphreys (Harvard Institutes of Medicine, Boston, MA), Matthias Meier (F. Hoffmann-LaRoche Ltd, Basel, Switzerland), Shahnaz Shahinfar (The Children's Hospital of Philadelphia, Philadelphia, PA), Katalin Susztak (University of Pennsylvania, Philadelphia, PA), Aliza Thompson (US Food & Drug Administration, Silver Spring)
Identifying and prosecuting drug targets is challenging due to a poor understanding of pathogenesis and few biomarkers. This symposium identifies targets for preventive or therapeutic interventions and discusses challenges in clinical development.
Thursday, June 26, 2014 | 7:45 AM - 6:00 PM
Keynote Speaker: Robin Franklin (Wellcome Trust – MRC Cambridge Stem Cell Institute, University of Cambridge)
This translational conference will highlight biological and clinical findings in myelin development, new techniques for brain imaging and for screening molecular targets, and novel therapeutics that promote remyelination.
Tuesday, May 20, 2014 | 8:30 AM - 5:00 PM
Speakers: Timothy Charlebois (Pfizer), David King (AnaptysBio Inc.), William M. Pardridge (Brain Research Institute, UCLA), Steven J. Projan (MedImmune), Sachdev Siddhu (University of Toronto), E. Sally Ward (UT Southwestern), Patrick C. Wilson (The University of Chicago), K. Dane Wittrup (Massachusetts Institute of Technology)
New technologies are pivotal in developing next-generation biologics. This symposium highlights novel technologies in the discovery of new biologics, elucidating in vivo mechanisms of therapeutic proteins, and manufacturing and delivery processes.
Friday, May 9, 2014 | 8:00 AM - 4:00 PM
Speakers: Carmela R. Abraham (Boston University School of Medicine), Eric H. Baehrecke (University of Massachusetts Medical School), Nir Barzilai (Albert Einstein College of Medicine), Jerry R. Colca (Metabolic Solutions Development Company), Brendan D. Manning (Harvard School of Public Health), Beth Stevens (Harvard Medical School), D. Martin Watterson (Northwestern University Feinberg School of Medicine), Haung Yu (Columbia University), Jeffrey W. Kelly (The Scripps Research Institute), Richard I. Morimoto (Northwestern University)
Age is the major risk factor for Alzheimer's disease, and key pathways in aging biology offer targets for novel drugs. Explore recent advances in the science of aging and innovative drug discovery for Alzheimer's and other neurodegenerative diseases.
Monday, May 5, 2014 | 7:30 AM - 3:00 PM
Speakers: Fareed Abdullah (South African National AIDS Council, Pretoria, South Africa), Frederick Altice (Yale School of Medicine, New Haven, CT, USA), Joe Amon (Human Rights Watch, New York, NY, USA), Chasity Andrews (Aaron Diamond AIDS Research Center, New York, NY, USA), Chris Beyrer (Johns Hopkins Bloomberg School of Public Health, Baltimore, PA, USA), Frances Cowan (Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Zimbabwe), Anna-Louise Crago (University of Toronto, Canada), Steven Deeks (University of California - San Francisco, CA, USA), Jerome Kim (Walter Reed Army Institute of Research, Bethesda, MD, USA), Luiz Loures (UNAIDS, Geneva, Switzerland), Kristen Marks (Weill Cornell Medical College, New York, NY, USA), Daniel Raymond (Harm Reduction Coalition, New York, NY, USA), Pavlo Smyrnov (International HIV/AIDS Alliance in Ukraine, Ukraine)
The UNAIDS' vision of zero new HIV infections, zero AIDS-related deaths and zero discrimination provides a clear path for HIV research and policy. This symposium convenes clinicians, scientists, activists and policy-makers with the shared goal of improving outcomes for HIV in key vulnerable populations.
Organizers: Howard Fillit (Alzheimer's Drug Discovery Foundation), Kevin J. Lee (Lawrence Ellison Foundation), and Jennifer Henry (The New York Academy of Sciences)
This eBriefing explores advances in the science of aging and in drug discovery for Alzheimer's and other neurodegenerative diseases.
Organizers: Chris Beyrer (Johns Hopkins Bloomberg School of Public Health), Peter Godfrey-Faussett (UNAIDS), Ani Shakarishvili (UNAIDS), Yegor Voronin (Global HIV Vaccine Enterprise), and Jennifer Henry (The New York Academy of Sciences)
The UNAIDS vision of zero new HIV infections, zero AIDS-related deaths, and zero discrimination calls for a global approach to HIV research and policy. This eBriefing focuses on improving outcomes for HIV in key vulnerable populations.
Edited by Noel R. Rose
(Johns Hopkins University, Baltimore, Maryland)
This sixth installment of The Year in Immunology series focuses on myeloid cells and inflammation.
Organizers: Johanna P. Daily (Albert Einstein College of Medicine), David A. Fidock (Columbia University Medical Center), and Jennifer Henry (The New York Academy of Sciences)
Keynote Speakers: Jane M. Carlton (New York University), Rick M. Fairhurst (National Institute of Allergy and Infectious Diseases, NIH), and Terrie E. Taylor (Michigan State University)
This eBriefing highlights a symposium held on World Malaria Day to examine breakthroughs in pathophysiology, drug development, and pre-erythrocytic and liver-stage biology.
Foods high in antioxidants are believed to fight oxidative stress. But what is oxidative stress? Two scientists from a recent NYAS conference break it down and discuss whether antioxidants have superpowers.
Delve into the world of prebiotic and probiotic science. We talk to three people in the field and learn why keeping the good microbes in our bodies happy means a lot for health.
Neuropsychologist Jeffrey Halperin is using behavioral therapy on preschoolers with attention deficit hyperactivity disorder (ADHD). He hopes to train their brains to develop in new ways and if effective, his therapies could offer permanent, drug-free treatment for the disorder.
Researchers at Harvard have discovered why the headaches of some migraine sufferers worsen when the person is exposed to light. Rami Burstein, the study's senior author, explains what's happening in the brain, and how they made the breakthrough.
Translational Medicine Initiative
The Translational Medicine Initiative represents a three-year partnership between the New York Academy of Sciences and the Josiah Macy, Jr. Foundation to support the translation of basic science research into clinical applications.
Learn more at www.nyas.org/TransMed.